Recent DMAC News
- DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke • Business Wire • 04/17/2024 08:08:00 PM
- DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results • Business Wire • 03/19/2024 08:15:00 PM
- DiaMedica Therapeutics Announces Poster Presentation at International Stroke Conference • Business Wire • 01/29/2024 09:13:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/23/2024 09:23:11 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/23/2024 09:12:31 PM
- DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer • Business Wire • 01/22/2024 01:23:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 10:05:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 09:47:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 09:39:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 09:30:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/16/2023 09:37:28 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:55:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 09:52:34 PM
- DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial Results • Business Wire • 11/13/2023 09:28:00 PM
- DiaMedica Therapeutics to Attend the 14th Annual Craig-Hallum Alpha Select Conference November 16, 2023 • Business Wire • 11/09/2023 01:25:00 PM
- DiaMedica Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update November 14, 2023 • Business Wire • 11/06/2023 01:23:00 PM
- DiaMedica Therapeutics Announces the Appointment of Ambarish Shah, Ph.D. as Chief Technology Officer • Business Wire • 09/12/2023 12:13:00 PM
- DiaMedica Therapeutics to Participate at Lake Street’s 7th Annual Best Ideas Growth Conference • Business Wire • 09/06/2023 12:35:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/05/2023 08:15:57 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:29:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 08:25:12 PM
- DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2023 Financial Results • Business Wire • 08/14/2023 08:13:00 PM
- DiaMedica Therapeutics to Report Second Quarter 2023 Financial Results and Provide a Business Update August 15, 2023 • Business Wire • 08/08/2023 12:32:00 PM
- DiaMedica Therapeutics to Attend the American Academy of Neurology Summer Conference • Business Wire • 07/18/2023 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 07/10/2023 08:16:27 PM
VPR Brands LP Reports Record Annual Financial Performance for Fiscal Year 2023 • VPRB • Apr 19, 2024 11:24 AM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • GCTK • Apr 17, 2024 8:00 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM